-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Cullinan Therapeutics, Lowers Price Target to $24

Benzinga·05/12/2025 20:10:02
Listen to the news
UBS analyst David Dai maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and lowers the price target from $30 to $24.